These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 34050896)
1. The Role of Finerenone in the Management of Diabetic Nephropathy. Veneti S; Tziomalos K Diabetes Ther; 2021 Jul; 12(7):1791-1797. PubMed ID: 34050896 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective. Marzolla V; Infante M; Armani A; Rizzo M; Caprio M Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659 [TBL] [Abstract][Full Text] [Related]
3. Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. Ruilope LM; Agarwal R; Chan JC; Cooper ME; Gansevoort RT; Haller H; Remuzzi G; Rossing P; Schmieder RE; Nowack C; Ferreira AC; Pieper A; Kimmeskamp-Kirschbaum N; Bakris GL Am J Nephrol; 2014; 40(6):572-81. PubMed ID: 25591469 [TBL] [Abstract][Full Text] [Related]
4. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. Wish JB; Pergola P Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502 [TBL] [Abstract][Full Text] [Related]
5. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Lv R; Xu L; Che L; Liu S; Wang Y; Dong B Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374 [TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone. Rico-Mesa JS; White A; Ahmadian-Tehrani A; Anderson AS Curr Cardiol Rep; 2020 Sep; 22(11):140. PubMed ID: 32910349 [TBL] [Abstract][Full Text] [Related]
8. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy. Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y; J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025 [TBL] [Abstract][Full Text] [Related]
9. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025 [TBL] [Abstract][Full Text] [Related]
10. The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic Nephropathy. Goenka L; Padmanaban R; George M Curr Clin Pharmacol; 2019; 14(2):78-83. PubMed ID: 30444201 [TBL] [Abstract][Full Text] [Related]
11. Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives. Sarafidis PA; Memmos E; Alexandrou ME; Papagianni A Curr Pharm Des; 2018; 24(46):5528-5536. PubMed ID: 30848187 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular and Renal Outcomes with Finerenone, a Selective Mineralocorticoid Receptor Antagonist. Palanisamy S; Funes Hernandez M; Chang TI; Mahaffey KW Cardiol Ther; 2022 Sep; 11(3):337-354. PubMed ID: 35737275 [TBL] [Abstract][Full Text] [Related]
13. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. Rossing P Kidney Int Suppl (2011); 2022 Apr; 12(1):27-35. PubMed ID: 35529090 [TBL] [Abstract][Full Text] [Related]
14. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes. Lerma EV; Wilson DJ Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of mineralocorticoid receptor antagonists with ACEI/ARB treatment for diabetic nephropathy: A meta-analysis. Zuo C; Xu G Int J Clin Pract; 2019 Aug; ():e13413. PubMed ID: 31464019 [TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid Receptor Antagonists in the Treatment of Diabetic Kidney Disease: Their Application in the Era of SGLT2 Inhibitors and GLP-1 Receptor Agonists. Cohen S; Sternlicht H; Bakris GL Curr Diab Rep; 2022 May; 22(5):213-218. PubMed ID: 35441935 [TBL] [Abstract][Full Text] [Related]
17. Finerenone in diabetic kidney disease: A systematic review and critical appraisal. Singh AK; Singh A; Singh R; Misra A Diabetes Metab Syndr; 2022 Oct; 16(10):102638. PubMed ID: 36223666 [TBL] [Abstract][Full Text] [Related]
18. Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease. Georgianos PI; Agarwal R Kidney Int Rep; 2021 Sep; 6(9):2281-2291. PubMed ID: 34514191 [TBL] [Abstract][Full Text] [Related]
19. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease. Raj R Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249 [TBL] [Abstract][Full Text] [Related]
20. Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review. Mavrakanas TA; Gariani K; Martin PY Eur J Intern Med; 2014 Feb; 25(2):173-6. PubMed ID: 24315413 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]